Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature

J Gastrointest Cancer. 2019 Sep;50(3):556-559. doi: 10.1007/s12029-017-0043-6.

Authors

Jun Takada¹, Hiroshi Araki², Noritaka Ozawa², Tomohiko Sugiyama², Masaya Kubota², Takashi Ibuka², Masahito Shimizu²

Affiliations

¹ Department of Gastroenterology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan. [email protected].
² Department of Gastroenterology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.

PMID: 29250745
DOI: 10.1007/s12029-017-0043-6

No abstract available

Publication types

Case Reports
Review

MeSH terms

Adenocarcinoma / blood
Adenocarcinoma / drug therapy*
Adenocarcinoma / secondary
Aged
Antibodies, Monoclonal, Humanized / pharmacology*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biopsy
Drug Resistance, Neoplasm
Fatal Outcome
Female
Gastric Mucosa / diagnostic imaging
Gastric Mucosa / metabolism
Gastric Mucosa / pathology
Humans
Ramucirumab
Stomach Neoplasms / blood
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / pathology
Tomography, X-Ray Computed
Treatment Outcome
Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors
alpha-Fetoproteins / analysis
alpha-Fetoproteins / metabolism

Substances

AFP protein, human
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
alpha-Fetoproteins
KDR protein, human
Vascular Endothelial Growth Factor Receptor-2